相关实验视频

Updated: Jul 11, 2025

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Published on: July 5, 2017

在第3期ATTR-ACT和正在进行的长期扩展研究中,塔法米迪斯在八分生患者中的有效性

Pablo Garcia-Pavia¹, Marla B Sultan², Balarama Gundapaneni³

¹Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, Madrid, Spain; Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Universidad Francisco de Vitoria (UFV), Pozuelo de Alarcón, Madrid, Spain.

JACC. Heart failure

|November 9, 2023

概括

塔法米迪斯在治疗所有年龄组的甲基氨酸转化素心肌病症 (ATTR-CM) 中表现出有效性. 这包括80岁及以上的老年人,他们显示生活质量改善和生存益处.

科学领域:

心脏病学心脏病学
药理学药理学是指药理学的学科.
临床试验临床试验

背景情况:

塔法米迪斯已获批准用于治疗跨甲基氨基基酸心肌病变 (ATTR-CM).
它的有效性最初是在Tafamidis in Transthyretin Cardiomyopathy临床试验 (ATTR-ACT) 中确立的.

研究的目的:

在老年患者 (年龄≥80岁) 中对塔法米迪斯疗效进行后期分析.
为了比较八十岁患者与ATTR-CM的年轻患者 (<80岁) 的结局.

主要方法:

从ATTR-ACT试验及其开放式长期延伸 (LTE) 研究中对80岁以下和80岁以上的患者进行分析.
评估有效性终点,包括6分钟步行测试 (6MWT),NT-proBNP水平,堪萨斯城心肌病问卷总结 (KCCQ-OS) 成绩和生存率.

主要成果:

在80岁以上的患者中,与安慰剂相比,tafamidis治疗在6MWT,NT-proBNP和KCCQ-OS中显示出显著的益处.
在LTE研究中,持续的tafamidis治疗与KCCQ-OS的较小下降以及八十岁的中位生存时间更长的趋势相关.
在80岁以下的患者中观察到类似的疗效,功能状况改善,NT-proBNP,KCCQ-OS和住院减少.

结论:

塔法米迪斯在治疗年轻 (<80岁) 和老年 (≥80岁) 患者群体中有效治疗ATTR-CM.
这项研究支持在广泛的年龄范围内使用tafamidis用于ATTR-CM管理.

关键词:

年龄的年龄年龄的年龄.氨基粉症是什么?年长的老人老年人老年人.心力衰竭与保存的喷射分数的心脏衰竭幸存率幸存率生存率

更多相关视频

Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults

Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults

Published on: December 9, 2014

Transcranial Pulse Stimulation for Alzheimer's Patients

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...